In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Humanigen (HGEN – Research Report), with a price target of $28.00. The company's shares closed last Thursday at $1.84, close to its 52-week low of $1.67. According to TipRanks.com, Pantginis ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -27.9% and a 17.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Humanigen with a $21.75 average price target.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-humanigens-stock-is-going-to-recover-5?utm_source=advfn.com&utm_medium=referral
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Humanigen Charts.
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Humanigen Charts.